Two weeks after returning from TRP EU in Amsterdam, some important aspects still linger in our thoughts. Especially, since we always try to bring back to the team @BIOEMTECH the key takeaways of worthwhile conferences and events and exploit the knowledge in our everyday practices.
Our 3 main points:
1️⃣ RLT research is governed by developers aiming at specific targets: PSMA (60), FAP (26), HER2 (20) & SSTR (12), however currently there are more than 80 different targets being studied while more than 100 developers are working on undisclosed targets.
2️⃣ Administered activity in clinical RLT is still governed by the activity used in Iodine therapies, since most safety data are still derived from the past. Dosimetry will play a significant role in adjusting this and avoiding underdosing patients just to be on the safe side. FDA is already open to such discussions, when enough supporting data are presented.
3️⃣ Phase 0 trials are essential to first image the biodistribution of a novel therapeutic compound, but using a low-dose therapeutic isotope is recommended over using a diagnostic analogue (e.g., low dose Lu177, rather than Ga68), since compounds’ conformation significantly changes with different isotopes. This will safely determine the real dosimetry data for upcoming Phase 1 dosing decisions.
🤔 Looking forward to seeing how this fast-paced field will evolve over the next months!